n/a
Abstract Title:

Apigenin alleviates neuroinflammation in a mouse model of Parkinson's disease.

Abstract Source:

Int J Neurosci. 2022 Jun 14:1-13. Epub 2022 Jun 14. PMID: 35698811

Abstract Author(s):

Gul Fatma Yarim, Filiz Kazak, Murat Yarim, Mahmut Sozmen, Bugra Genc, Ali Ertekin, Ayris Gokceoglu

Article Affiliation:

Gul Fatma Yarim

Abstract:

The aim of this study is to evaluate the effect of apigenin on inflammatory response in brain tissue in Parkinson's mouse model.Parkinson's disease model was induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sixty 8-10-weeks-old male C57BL/6 mice were randomly divided into four groups control, Parkinson, prophylaxis, and treatment. Control (0.9% NaCl 0.5 ml, 10 days, i.p.), Parkinson (25 mg/kg MPTP, 5 days, i.p.), prophylaxis (50 mg/kg apigenin, 5 days +25 mg/kg MPTP, 5 days, i.p.), and treatment (25 mg/kg MPTP, 5 days +50 mg/kg apigenin, 5 days). The expressions and protein levels of tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β), IL-6, IL-10, and transforming growth factor-beta (TGF-β) were determined using immunohistochemistry and enzyme-linked immunosorbent analysis.Apigenin administration attenuated MPTP-induced histopathological changes in brain tissue. Furthermore, apigenin reversed the changes in expressions and concentrations of TNF-α, IL-1β, IL-6, IL-10, and TGF-β.This study suggests that apigenin could be used as a neuroprotective option to attenuate neuroinflammation in Parkinson's disease.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.